SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2001
-----------------------
or
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________________ to ______________________
Commission file number 0-16752
-------
MEDSTONE INTERNATIONAL, INC.
--------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 66-0439440
--------------------------------------------------------------------------------
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
100 Columbia, Suite 100, Aliso Viejo, California 92656-4114
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (949) 448-7700
Not Applicable
--------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed, since last
report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
--- ----
The number of shares of the Common Stock of the registrant outstanding as of
August 7, 2001 was 4,198,220.
MEDSTONE INTERNATIONAL, INC.
INDEX TO FORM 10-Q
PART I. FINANCIAL INFORMATION
Page No.
--------
Item 1. Financial Statements:
Consolidated Balance Sheets
June 30, 2001 (Unaudited) and December 31, 2000 3
Condensed Consolidated Statements of Operations (Unaudited)
Three and Six Months Ended June 30, 2001 and 2000 4
Consolidated Statement of Stockholders' Equity (Unaudited)
Six Months Ended June 30, 2001 5
Condensed Consolidated Statements of Cash Flows (Unaudited)
Six Months ended June 30, 2001 and 2000 6
Notes to Unaudited Condensed Consolidated Financial Statements 7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 11
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 16
Item 2. Changes in Securities 16
Item 3. Defaults Upon Senior Securities 16
Item 4. Submission of Matters to a Vote of Security Holders 16
Item 5. Other Information 16
Item 6. Exhibits and Reports on Form 8-K 17
Signatures 18
MEDSTONE INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
June 30, December 31,
2001 2000
--------------- ----------------
(Unaudited)
ASSETS
------
Current assets:
Cash and cash equivalents $ 1,737,196 $ 945,610
Short-term investments held to maturity 4,485,899 5,223,659
Accounts receivable, less allowance for doubtful accounts
of $581,487 at June 30, 2001 and $477,180 at
December 31, 2000, respectively 4,250,534 4,165,563
Inventories, less allowance for inventory obsolescence
of $456,417 at June 30, 2001 and $457,088 at
December 31, 2000, respectively 6,129,723 6,103,051
Deferred tax assets 1,005,814 1,005,814
Prepaid expenses and other current assets 518,747 526,825
--------------- ----------------
Total current assets 18,127,913 17,970,522
Buildings, property and equipment, at cost:
Building 359,324 359,324
Lithotripters 12,977,158 12,316,739
Equipment, furniture and fixtures 2,940,931 2,784,217
Leasehold improvements 162,883 157,083
--------------- ----------------
16,440,296 15,617,363
Less accumulated depreciation and amortization (11,460,788) (10,440,172)
--------------- ----------------
Net property and equipment 4,979,508 5,177,191
--------------- ----------------
Goodwill, net 3,257,047 3,306,622
Investment in unconsolidated subsidiaries 1,300,763 1,263,598
Long-term receivable from unconsolidated subsidiary 2,000,000 2,000,000
Other assets, net 129,952 158,914
--------------- ----------------
$ 29,795,183 $ 29,876,847
=============== ================
LIABILITIES AND STOCKHOLDERS' EQUITY
-----------------------------------
Current liabilities:
Accounts payable $ 577,804 $ 657,878
Accrued expenses 513,849 580,232
Accrued income taxes 117,627 73,314
Accrued payroll expenses 270,392 347,034
Customer deposits 366,808 58,441
Deferred revenue 536,473 656,332
--------------- ----------------
Total current liabilities 2,382,953 2,373,231
Deferred tax liabilities 562,313 562,313
Minority interest 541,251 554,292
Deferred rent 84,106 78,697
Stockholders' equity:
Common stock - $.004 par value, 20,000,000 shares authorized,
5,742,670 shares issued and outstanding at both June 30,
2001 and December 31, 2000, respectively 22,971 22,971
Additional paid-in capital 19,646,388 19,646,388
Accumulated earnings 17,288,717 16,708,143
Accumulated other comprehensive income 41,573 55,395
Treasury stock, at cost, 1,544,450 and 1,434,450 shares at
June 30, 2001 and December 31, 2000, respectively (10,775,089) (10,124,583)
--------------- ----------------
Total stockholders' equity 26,224,560 26,308,314
--------------- ----------------
$ 29,795,183 $ 29,876,847
=============== ================
See accompanying notes.
3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2001 2000 2001 2000
---------- ---------- ----------- -----------
Revenues:
Procedures, maintenance fees and fee-for service $4,719,194 $4,656,903 $ 9,229,967 $ 9,307,221
Net equipment sales 744,678 1,177,500 1,097,859 2,506,544
Interest income 116,071 148,702 257,957 278,699
---------- ---------- ----------- -----------
Total revenues 5,579,943 5,983,105 10,585,783 12,092,464
Costs and expenses:
Costs of procedures and maintenance fees 2,677,076 2,685,084 5,510,106 5,433,133
Cost of equipment sales 671,539 843,230 1,021,827 1,717,338
Research and development 299,147 403,324 560,104 660,377
Selling 713,029 496,386 1,243,651 1,031,056
General and administrative 648,276 658,554 1,312,305 1,382,743
---------- ---------- ----------- -----------
Total costs and operating expenses 5,009,067 5,086,578 9,647,993 10,224,647
---------- ---------- ----------- -----------
Operating income 570,876 896,527 937,790 1,867,817
Other expense (income):
Gain on sale of investments (69,497) (298,154) (427,605) (1,080,710)
Other expense 19,033 41,155 52,376 51,265
---------- ---------- ----------- -----------
Total other expenses (income) (50,464) (256,999) (375,229) (1,029,445)
---------- ---------- ----------- -----------
Minority interests:
Minority interest in subsidiaries income 179,564 208,548 334,959 400,007
Equity in income from unconsolidated subsidiary (7,656) --- (37,165) ---
---------- ---------- ----------- -----------
Total minority interest 171,908 208,548 297,794 400,007
---------- ---------- ----------- -----------
Income before provision for income taxes 449,432 944,978 1,015,225 2,497,255
Provision for income taxes 219,651 389,990 434,651 1,019,990
---------- ---------- ----------- -----------
Net income $ 229,781 $ 554,988 $ 580,574 $ 1,477,265
========== ========== =========== ===========
Earnings per share
Basic $ .05 $ .12 $ .14 $ .32
========== ========== =========== ===========
Diluted $ .05 $ .12 $ .14 $ .32
========== ========== =========== ===========
Number of shares used in the computation of
earnings per share:
Basic 4,198,220 4,590,025 4,235,720 4,606,359
========== ========== =========== ===========
Diluted 4,198,609 4,591,319 4,240,728 4,611,010
========== ========== =========== ===========
See accompanying notes.
4
MEDSTONE INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Common Stock Accumulated
------------------------- Additional Other
Number of paid-in Accumulated Comprehensive Treasury
shares Amount capital earnings income (loss) Stock Total
------------- ---------- ------------ ------------- ------------- ------------- ------------
Balance at December 31, 2000 4,308,220 $ 22,971 $ 19,646,388 $ 16,708,143 $ 55,395 $ (10,124,583) $ 26,308,314
Net income --- --- --- 580,574 --- --- 580,574
Other comprehensive income:
Unrealized loss on foreign
currency translation, net --- --- --- --- (13,822) --- (13,822)
------------
Total comprehensive income 566,752
------------
Treasury stock repurchased (110,000) --- --- --- --- (650,506) (650,506)
------------- ---------- ------------ ------------- ------------- ------------- ------------
Balance at June 30, 2001
(Unaudited) 4,198,220 $ 22,971 $ 19,646,388 $ 17,288,717 $ 41,573 $ (10,775,089) $ 26,224,560
============= ========== ============ ============= ============= ============= ============
See accompanying notes.
5
MEDSTONE INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Six months ended June 30, 2001 and 2000
(Unaudited)
2001 2000
----------- -----------
Cash flows from operating activities:
Net income $ 580,574 $ 1,477,265
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 1,080,129 1,204,978
Provision for doubtful accounts 110,000 ---
Provision for inventory obsolescence 84,000 40,000
Gain on sale of long-term investments (427,605) (1,080,710)
Minority interest in partnerships 334,959 400,007
Minority equity in unconsolidated subsidiary (37,165) ---
Changes in assets and liabilities:
Accounts receivable (194,971) (1,322,466)
Inventories (110,672) (406,442)
Prepaid expenses and other current assets 8,078 20,149
Accounts payable and accrued expenses (137,826) 162,194
Accrued payroll expenses (76,642) 42,764
Accrued income taxes 72,028 76,321
Deferred revenue (119,859) (5,525)
Customer deposits 308,367 5,900
----------- -----------
Other, net (15,308) 105,822
----------- -----------
Net cash provided by operating activities 1,458,087 720,257
----------- -----------
Cash flows from investing activities:
Purchase of short-term investments (5,602,921) (7,767,338)
Proceeds from sales of short-term investments 6,340,681 8,629,990
Investment in other entities --- (1,000,000)
Proceeds from sale of long-term investments 427,605 1,080,710
Distribution of minority interest (348,000) (272,000)
Purchase of property and equipment, net (830,138) (497,485)
----------- -----------
Net cash provided by (used in) investing
activities (12,773) 173,877
----------- -----------
Cash flows from financing activities:
Proceeds from issuance of common stock --- 5,190
Proceeds of treasury stock (650,506) (729,976)
Deferral of rent payments 5,409 ---
Loan payments (8,631) (17,988)
----------- -----------
Net cash used in financing activities (653,728) (742,774)
----------- -----------
Net increase in cash and equivalents 791,586 151,360
Cash and equivalents at beginning of period 945,610 1,061,422
----------- -----------
Cash and equivalents at end of period $ 1,737,196 $ 1,212,782
=========== ===========
Supplemental cash flow disclosures:
Cash paid during the period for:
Income taxes $ 396,452 $ 945,926
See accompanying notes.
6
MEDSTONE INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2001
A. Basis of presentation
The accompanying condensed consolidated financial statements include the
accounts of Medstone International, Inc. and its subsidiaries (the Company).
All significant intercompany transactions and accounts have been eliminated.
In the opinion of the Company's management, the accompanying unaudited
condensed consolidated financial statements include all adjustments (which
consist only of normal recurring adjustments) necessary for a fair presentation
of its consolidated financial position at June 30, 2001 and consolidated results
of operations and cash flows for the periods presented. Although the Company
believes that the disclosures in these financial statements are adequate to make
the information presented not misleading, certain information and disclosures
normally included in financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted. These financial
statements should be read in conjunction with the Company's audited financial
statements included in the Company's 2000 Annual Report on Form 10-K filed with
the Securities and Exchange Commission on March 30, 2001. Results of operations
for the three and six months ended June 30, 2001 are not necessarily indicative
of results to be expected for the full year.
The preparation of financial statements in accordance with generally accepted
accounting principles requires management to make assumptions that affect the
amounts reported in the financial statements and accompanying notes. Actual
results could differ from these estimates.
B.Recently Issued Accounting Pronouncement
In June 2001, the Financial Accounting Standards Board issued Statements of
Financial Accounting Standards No. 141, Business Combinations, and No. 142,
Goodwill and Other Intangible Assets, effective for fiscal years beginning after
December 15, 2001. Under the new rules, goodwill and intangible assets deemed
to have indefinite lives will no longer be amortized but will be subject to
annual impairment tests in accordance with the Statements. Other intangible
assets will continue to be amortized over their useful lives.
The Company will apply the new rules on accounting for goodwill and other
intangible assets beginning in the first quarter of 2002. Application of the
nonamortization provisions of the Statement is expected to result in an increase
in net income, after tax, of approximately $60,000 ($.01 per share) per year.
During 2002, the Company will perform the first of the required impairment tests
of goodwill and indefinite lived intangible assets as of January 1, 2002 and has
not yet determined what the effect of these tests will be on the earnings and
financial position of the Company.
7
C. Accumulated Other Comprehensive Loss
The components of other comprehensive loss are as follows:
Currency
Translation
Adjustment
----------
Balance at December 31, 2000 $55,395
Foreign currency translation adjustments (13,822)
--------
Balance at June 30, 2001 $41,573
========
The functional currency of the investment in foreign subsidiary is considered
to be the United States dollar.
The earnings associated with the Company's investment in its foreign
subsidiary are considered to be permanently invested and no provision for U.S.
federal and state income taxes on those earnings or translation adjustments has
been provided.
For the three months ended June 30, 2001 and 2000, total comprehensive income
was $220,482 and $606,042, respectively, For the six months ended June 30, 2001
and 2000, total comprehensive income was $566,752 and $1,588,522, respectively.
D. Business Segments
The Company operates in two business segments, equipment sales and fees for
procedures, maintenance and management.
Three months ended Six months ended
June 30, 2001 June 30, 2000 June 30, 2001 June 30, 2000
------------------- ------------- -------------- -------------
Revenue:
Equipment sales $ 744,678 $ 1,177,500 $ 1,097,859 $ 2,506,544
Fees for procedures,
maintenance and
management 4,719,194 4,656,903 9,229,967 9,307,221
---------- ----------- ----------- -----------
$5,463,872 $ 5,834,403 $10,327,826 $11,813,765
========== =========== =========== ===========
Operating income (loss):
Equipment sales (35,918) $ 113,757 $ (123,691) $ 222,070
Fees for procedures,
maintenance and
management 606,794 1,039,769 1,061,481 2,675,192
---------- ----------- ----------- -----------
$570,876 $1,153,526 $ 937,790 $ 2,897,262
========== =========== =========== ===========
8
E. Per share information
The Company has adopted SFAS No. 128 "Earnings Per Share," and applied this
pronouncement to all periods presented. This statement requires the
presentation of both basic and diluted net income per share for financial
statement purposes. Basic net income per share is computed by dividing income
available to common stockholders by the weighted average number of common shares
outstanding. Diluted net income per share includes the effect of the potential
shares outstanding, including dilutive stock options and warrants using the
treasury stock method. All earnings per share amounts for all periods have been
restated to conform with the SFAS No. 128 requirements and the accounting rules
set forth in Staff Accounting Bulletin 98 issued by the Securities and Exchange
Commission on February 3, 1998.
The following table sets forth the computation of earnings per share:
Three Months Ended June 30, Six Months Ended June 30,
---------------------------- -------------------------
2001 2000 2001 2000
----- ---- ---- ----
Numerator: Net income $ 229,781 $ 554,988 $ 580,574 $1,477,265
========== ========== ========== ==========
Denominator for weighted
average shares outstanding 4,198,220 4,590,025 4,235,720 4,606,359
========== ========== ========== ==========
Basic earnings per share $ .05 $ .12 $ .14 $ .32
========== ========== ========== ==========
Effect of dilutive securities:
Weighted average shares
outstanding 4,198,220 4,590,025 4,235,720 4,606,359
Stock options 389 1,294 5,008 4,651
---------- ---------- ---------- ----------
Denominator for diluted earnings
per share 4,198,609 4,591,319 4,240,728 4,611,010
========== ========== ========== ==========
Diluted earnings per share $ .05 $ .12 $ .14 $ .32
========== ========== ========== ==========
Common equivalent shares result from the assumed exercise of outstanding
dilutive securities when applying the treasury stock method. Fully diluted per
share information is not presented for periods in which the effect is
antidilutive.
F. Inventories
At June 30, 2001 and December 31, 2000, inventories consisted of the
following:
June 31, December 31,
2001 2000
---------- ------------
Raw materials $4,656,119 $3,888,640
Work in process 239,034 231,175
Finished goods 1,234,570 1,983,236
---------- ----------
$6,129,723 $6,103,051
========== ==========
9
G. Contingencies
From time to time, the Company is subject to legal actions and claims
for personal injuries or property damage related to patients who use its
products. The Company has obtained a liability insurance policy providing
coverage for product liability and other claims. Management does not believe
that the resolution of any current proceedings will have a material financial
impact on the Company or the condensed consolidated financial statements.
H. Stock Repurchase Plan
In the second quarter of 2001 the Company purchased a total of 25,000
shares at an aggregate cost of $144,469, completing the Company's latest Stock
Repurchase Plan. Under all of the Company's stock repurchase plans a total of
1,544,450 shares have been repurchased at a total cost of $10,775,089.
I. Subsequent Events
Sale of Cardiac Science Stock
-----------------------------
Subsequent to June 30, 2001, the Company sold 60,700 shares of its holdings
of Cardiac Science, Inc., for gross proceeds of approximately $149,000 in cash.
The Company still holds 25,300 shares of Cardiac Science, Inc.
10
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
The following discussion and analysis should be read in conjunction with
the Company's audited financial statements and Management's Discussion and
Analysis of Financial Condition and Results of Operations included in the
Company's 2000 Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 30, 2001.
Results of Consolidated Operations
General
Medstone manufactures, markets and maintains lithotripters, and continues
to expand its Fee-for-Service Program to supply lithotripsy equipment to
providers on a per procedure basis. The lithotripters manufactured by Medstone
are approved to treat both kidney stones and gallstones. The Company is also
marketing a urology imaging and treatment table, used for various urological
functions, mobile urology and pain management tables to serve the mobile
treatment market and various radiology room equipment, capitalizing on the
relationships that the Company has with radiology equipment manufacturers. To
date, the Company's consolidated revenues have come primarily from Medstone's
lithotripsy business.
As a manufacturer of medical devices, the Company has been vertically
integrating by offering its medical devices directly to providers. It currently
offers lithotripsy procedures using 15 mobile systems, two fixed sites and 23
transmobile lithotripters located throughout the United States on a per
procedure basis. With the ability to offer quality equipment at reasonable
prices, Medstone intends to continue the growth of this manufacturer direct
business.
Results of Operations
Three Months ended June 30, 2001 Compared to Three Months Ended June 30, 2000
-----------------------------------------------------------------------------
The Company recognized total revenue of $5.6 million in the second quarter
of 2001 compared to $6.0 million in the second quarter of 2000, or a 7%
decrease. Revenues from procedures, maintenance and management fees increased
from $4.656 million in the three months ended June 30, 2000 to $4.719 million in
the three months ended June 30, 2001 due to higher patient counts on the
Company's fee-for-service equipment although average per patient reimbursement
declined. The revenues for radiology and spares activity also increased in the
current quarter compared to the same period in the prior year. Offsetting these
increases were declines in the third party procedure fee as volume remained
steady but per patient reimbursement declined. Equipment revenues decreased to
$0.7 million in the quarter ended June 30, 2001 from $1.2 million in the
comparable quarter of the prior year, or a 37% decrease, as the Company shipped
two lithotripsy systems and 1 radiology suite in the U.K. in 2000 versus 1 litho
system and 31 various imaging tables in the quarter ended June 30, 2001.
Interest income decreased by 22% in the second quarter of 2001 when
compared to the same period of the prior year due to a significant decline in
investment yields and a decreased average
11
invested balance.
Recurring revenue cost of sales decreased to 57% of sales in the quarter
ended June 30, 2001 compared to 58% in the same quarter of the prior year. This
is due to lower depreciation and equipment rental expenses as the fee-for-
service revenue stream incorporates more fixed site fee-for-service units and
older mobile vans are fully depreciated. Cost of sales on equipment sales
increased to 90% of sales in the three months ended June 30, 2001 compared to
72% of sales in the same period of 2000. This increase is due to a higher cost
of sales of imaging tables and increased costs of production on lithotripsy
equipment. Overall cost of sales, as a percentage of revenue (excluding
interest), increased to 61% in the second quarter of 2001 compared to 60% in the
second quarter of 1999.
Research and development costs decreased to $299,000 in the second quarter
of 2001 compared to $403,000 in the second quarter of 2000 or a decrease of 26%
due to decreased UroPro 2000 development spending in the current year as the
project was substantially completed in the first quarter of 2001.
Selling costs increased to $713,000 in the second quarter of 2001 compared
to $496,000 in the second quarter of 2000, a change of $217,000 or 44% due to
higher payroll expenses as the Company steps up its sales and marketing staff
for the UroPro 2000 sales effort and increased bad debt expense.
General and administrative expenses decreased by $10,000 or 2% in the three
months ended June 30, 2001 compared to the same period in the prior year due to
lower consulting expenses partially offset by slightly higher audit expenses.
Gain on sale of investments was approximately $69,000 in the quarter ended
June 30, 2001 compared to $298,000 in the three months ended June 30, 2000 as
the Company sold 28,000 shares of Cardiac Science, Inc. common stock in the
current year, whereas the Company sold 53,500 shares of Cardiac Science in the
same period of 2000. The net book value of all shares was $0.
Total minority interest decreased to $172,000 in the three months ended
June 30, 2001 compared to $209,000 in the same period of the prior year due to
lower profits in the Northern Nevada and Southern Idaho operations and
recognition of equity income from Medicredit.com, Inc. operations in 2001.
Provision for income taxes for the second quarter of 2001 decreased by
$170,000 as a result of lower taxable income in the current year when compared
to the same period of 2000.
Six Months Ended June 30, 2001 Compared to Six Months Ended June 30, 2000
-------------------------------------------------------------------------
The Company recorded total revenue of $10.6 million in the first six months
of 2001 or a 12% decrease compared to $12.1 million in the corresponding period
of 2000. Revenues from procedures, maintenance and management fees decreased by
$77,000, or 1%, due to lower average reimbursement per patient even as total
patient count increased by 4% in the current year, to over 13,800 patients.
Equipment revenue decreased by $1,409,000, or 56%, as lithotripter shipments
decreased from 5 in the six months ended June 30, 2000 to 1 in the same period
of 2001. Partially
12
offsetting this decline is the increased activity in the Company's imaging
tables, as the Company has shipped 47 various types of tables in 2001 with no
corresponding units sold in 2000.
Interest income decreased by 7% for the first six months of 2001 when
compared to the same period of the prior year as slightly higher interest yields
were earned on a substantially lower average invested balance.
Procedure, maintenance and management fee cost of sales increased to 60% of
revenue in the six months ended June 30, 2001 compared to 58% in the same period
of the prior year as costs stabilized in the fee-for-service program with a
corresponding decrease in the per patient revenue realized. Cost of sales on
equipment sales increased to 93% of revenue in the first six months of 2001
compared to 69% of revenue in the first six months of 2000 due to lower margins
on imaging tables. Overall cost of sales, as a percentage of revenue
(excluding interest), increased slightly to 63% in the first half of 2001
compared to 61% in the first half of 2000.
Research and development costs decreased by $100,000, or 15% in the first
six months of 2001 when compared to the same period of 2000 as the Company had
funded its development of the UroPro-2000 urology imaging table in 2000 without
a corresponding major development project in the current year.
Selling costs increased by 21%, or $213,000, in the first half of 2001
compared to the same period of 2000 due to higher tradeshow, payroll and outside
services with the introduction of the UroPro 2000 and the Company's expansion
into radiographic equipment sales.
General and administrative expenses decreased by 5%, or $70,000, in the six
months ended June 30, 2001 compared to the first six months of 2000 due to lower
consulting expense and lower professional fees due to the 2000 acquisition of an
ownership interest in Medicredit.com, Inc., partially offset by legal expenses
resulting from the release of final Stark II regulations.
Gain on sale of investments was $428,000 in the six months ended June 30,
2001 compared to $1,081,000 in the six months ended June 30, 2000. In 2001,
the Company sold a total of 101,000 shares of Cardiac Science common stock
whereas 193,667 shares of Cardiac Science common stock and 5,000 shares of
Genstar Therapeutics Corp. (formerly Urogen Corp.) were sold during the same
period in 2000. The net book value of all shares sold was $0.
Minority interest decreased by 26% in the six months ended June 30, 2001
when compared to the same period of the prior year due to decreased profits in
the partnership operations and recognition of equity earnings from
Medicredit.com, Inc.
Provision for income taxes decreased to $435,000 in the first six months of
2001 compared to $1,020,000 for the same period of 2000 as a result of lower
taxable income in the current year.
13
Liquidity and Capital Resources
-------------------------------
At June 30, 2001, the Company had cash and short-term investments of
approximately $6.2 million. These funds were generated from continuing
operating activities and from the Company's initial public offering in June
1988.
The Company's long-term capital expenditure requirements will depend on
numerous factors, including the progress of the Company's research and
development programs, the time required to obtain regulatory approvals, the
resources that the Company devotes to the development of self-funded products,
proprietary manufacturing methods and advanced technologies, the costs of
acquisitions and/or new revenue opportunities, the ability of the Company to
obtain additional licensing arrangements and to manufacture products under those
arrangements, and the demand for its products if and when approved and possible
acquisitions of products, technologies and companies.
The Company believes that its existing working capital and funds
anticipated to be generated from operations will be sufficient to meet the cash
needs for continuation of its present operations during 2001.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Forward-looking statements in this report, including without limitation,
statements relating to the Company's plans, strategies, objectives,
expectations, intentions and adequacy of resources, are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties including without limitation the following: (i) the Company's
plans, strategies, objections, expectations and intentions are subject to change
at any time at the discretion of the Company, (ii) the Company's plans and
results of operations will be affected by the Company's ability to manage its
growth; (iii) the Company's businesses are highly competitive and the entrance
of new competitors into or the expansion of the operations by existing
competitors in the Company's markets and other changes could adversely affect
the Company's plans and results of operations; and (iv) other risks and
uncertainties indicated from time to time in the Company's filings with the
Securities and Exchange Commission.
14
MEDSTONE INTERNATIONAL, INC.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
-----------------
Previously reported.
Item 2. Changes in Securities
---------------------
None
Item 3. Defaults upon Senior Securities
-------------------------------
None
Item 4. Submission of Matters to a Vote of Security Holders
---------------------------------------------------
(a) The annual meeting of stockholders of the Company was held on June
20, 2001.
(b) The election of four board of directors of the Company was held.
The number of shares cast for each of the individuals listed below
to serve until the next Annual Meeting of stockholders and until
their successors are elected and have qualified was as follows:
NAME FOR WITHHELD
---- --- --------
David V. Radlinski 5,186,137 264,744
Frank R. Pope 5,218,437 232,444
Donald John Regan 5,217,991 232,890
Michael C. Tibbitts 5,217,837 233,044
David A. Reed 5,217,556 233,325
The ratification of the appointment of Ernst & Young, LLP as
independent accountants of the Company for the year ending
December 31, 2001.
For 5,436,781
Against 2,800
Abstain 11,300
Item 5. Other Information
None
Item 6. Exhibits and Reports on Form 8-K
--------------------------------
(a) The following exhibits are included herein:
None.
(b) Reports on Form 8-K.
None
15
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Medstone International, Inc.
----------------------------
A Delaware corporation
Date: August 13, 2001 /s/ Mark Selawski
------------------------------------
Mark Selawski
Chief Financial Officer
(Principal financial and
accounting officer)
16